Abstract:We investigate binding of linoleate and other potential ligands to the recently discovered fatty acid binding site in the SARS-CoV-2 spike protein, using docking and molecular dynamics simulations.S imulations suggest that linoleate and dexamethasone stabilizet he locked spike conformation, thus reducing the opportunity for ACE2 interaction. In contrast, cholesterol may expose the receptor-binding domain by destabilizing the closed structure,p referentially binding to ad ifferent site in the hinge region of th… Show more
“…ISO was identified, among other retinoids, to inhibit SARS-CoV-2 replication in Vero E6 cells. Shoemark et al 1 noted that ISO may bind to the SARS-CoV-2 spike protein at SARS-CoV-2 spike fatty acid site, influencing the conformational changes required for receptor binding, stabilizing the locked ACE2 conformation of the spike protein. That reduces the opportunity for receptor-mediated cell entry via interaction with ACE2.…”
Section: Could Isotretinoin Be a Protective Agent Against Covid-19?: A Dermatologist Perspectivementioning
confidence: 99%
“…In this way, isotretinoin may affect viral entry, particularly in the early stage of the infection process. 1 Moreover, ISO upregulates the host antiviral response, through stimulation of interferon-1 (IFN-I) secretion, potentiating immune response to it, and eventually reduces viral infectivity. 1 Spike protein interaction is limited not only to ACE2, but also to neuropilin receptors (NRPs) in cells where ACE2 expression is low.…”
Section: Could Isotretinoin Be a Protective Agent Against Covid-19?: A Dermatologist Perspectivementioning
confidence: 99%
“…1 Moreover, ISO upregulates the host antiviral response, through stimulation of interferon-1 (IFN-I) secretion, potentiating immune response to it, and eventually reduces viral infectivity. 1 Spike protein interaction is limited not only to ACE2, but also to neuropilin receptors (NRPs) in cells where ACE2 expression is low. Notably, NRPs are highly expressed in human lung tissue and olfactory epithelium compared to ACE2.…”
Section: Could Isotretinoin Be a Protective Agent Against Covid-19?: A Dermatologist Perspectivementioning
“…ISO was identified, among other retinoids, to inhibit SARS-CoV-2 replication in Vero E6 cells. Shoemark et al 1 noted that ISO may bind to the SARS-CoV-2 spike protein at SARS-CoV-2 spike fatty acid site, influencing the conformational changes required for receptor binding, stabilizing the locked ACE2 conformation of the spike protein. That reduces the opportunity for receptor-mediated cell entry via interaction with ACE2.…”
Section: Could Isotretinoin Be a Protective Agent Against Covid-19?: A Dermatologist Perspectivementioning
confidence: 99%
“…In this way, isotretinoin may affect viral entry, particularly in the early stage of the infection process. 1 Moreover, ISO upregulates the host antiviral response, through stimulation of interferon-1 (IFN-I) secretion, potentiating immune response to it, and eventually reduces viral infectivity. 1 Spike protein interaction is limited not only to ACE2, but also to neuropilin receptors (NRPs) in cells where ACE2 expression is low.…”
Section: Could Isotretinoin Be a Protective Agent Against Covid-19?: A Dermatologist Perspectivementioning
confidence: 99%
“…1 Moreover, ISO upregulates the host antiviral response, through stimulation of interferon-1 (IFN-I) secretion, potentiating immune response to it, and eventually reduces viral infectivity. 1 Spike protein interaction is limited not only to ACE2, but also to neuropilin receptors (NRPs) in cells where ACE2 expression is low. Notably, NRPs are highly expressed in human lung tissue and olfactory epithelium compared to ACE2.…”
Section: Could Isotretinoin Be a Protective Agent Against Covid-19?: A Dermatologist Perspectivementioning
“…In this work, we analyzed full-length models of 7 trimeric glycosylated SARS-CoV-2 S protein variants, derived from the prefusion conformation of the cryo-EM structure 6VSB [3a] , in which the Receptor Binding Domain of chain A (RBD-A) is in an "up" conformation, exposed to interaction with host cell receptors and potential targeting by Abs. The data from our energetic analyses can be aptly integrated in the characterization of the properties of S and other SARS-CoV-2 proteins from long scale simulations, such as those recently presented by Zimmerman et al coworkers [18] , Casalino et al [17e] , Spinello et al [19] , Oliveira et al [20] , Shoemark et al [21] , and Wang et al [22] .…”
The SARS-CoV-2 spike (S) protein is exposed on the viral surface and is the first point of contact between the virus and the host. For these reasons it represents the prime target for Covid-19 vaccines. In recent months, variants of this protein have started to emerge. Their ability to reduce or evade recognition by S-targeting antibodies poses a threat to immunological treatments and raises concerns for their consequences on vaccine efficacy.To develop a model able to predict the potential impact of S-protein mutations on antibody binding sites, we performed unbiased multi-microsecond molecular dynamics of several glycosylated S-protein variants and applied a straightforward structure-dynamics-energy based strategy to predict potential changes in immunogenic regions on each variant. We recover known epitopes on the reference D614G sequence. By comparing our results, obtained on isolated S-proteins in solution, to recently published data on antibody binding and reactivity in new S variants, we directly show that modifications in the S-protein consistently translate into the loss of potentially immunoreactive regions. Our findings can thus be qualitatively reconnected to the experimentally characterized decreased ability of some of the Abs elicited against the dominant S-sequence to recognize variants. While based on the study of SARS-CoV-2 Spike variants, our computational epitope-prediction strategy is portable and could be applied to study immunoreactivity in mutants of proteins of interest whose structures have been characterized, helping the development/selection of vaccines and antibodies able to control emerging variants.
“…For instance, maintenance of host interior homeostasis on vitamins (e.g. vitamin D, retinoids, vitamin K2) and metabolites of microbiota, which provide anti-virus properties and/or better Treg responses for anti-inflammatory reactions (179)(180)(181)(182)(183)(184), may regulate immunity and reduce mortality of an emerging infection.…”
Different emerging viral infections may emerge in different regions of the world and pose a global pandemic threat with high fatality. Clarification of the immunopathogenesis of different emerging viral infections can provide a plan for the crisis management and prevention of emerging infections. This perspective article describes how an emerging viral infection evolves from microbial mutation, zoonotic and/or vector-borne transmission that progresses to a fatal infection due to overt viremia, tissue-specific cytotropic damage or/and immunopathology. We classified immunopathogenesis of common emerging viral infections into 4 categories: 1) deficient immunity with disseminated viremia (e.g., Ebola); 2) pneumocytotropism with/without later hyperinflammation (e.g., COVID-19); 3) augmented immunopathology (e.g., Hanta); and 4) antibody-dependent enhancement of infection with altered immunity (e.g., Dengue). A practical guide to early blocking of viral evasion, limiting viral load and identifying the fatal mechanism of an emerging viral infection is provided to prevent and reduce the transmission, and to do rapid diagnoses followed by the early treatment of virus neutralization for reduction of morbidity and mortality of an emerging viral infection such as COVID-19.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.